Article
Oncology
Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta Pal
Summary: This study found that specific plasma cytokines were associated with clinical benefit in patients with renal cell carcinoma receiving VEGF-TKI or ICI therapy. These findings support further investigation into plasma cytokines as potential biomarkers for renal cell carcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Amrit S. Gonugunta, Mitchell S. von Itzstein, Hong Mu-Mosley, Farjana Fattah, J. David Farrar, Angela Mobely, Sawsan Rashdan, Sunny Lai, Salman F. Bhai, Bonnie L. Bermas, David Karp, Quan-Zhen Li, Edward K. Wakeland, David E. Gerber
Summary: This case study demonstrates the potential for late-onset changes in humoral and cellular immunity in patients receiving ICI treatment. Corticosteroid administration resulted in immediate and profound decreases in cytokines, autoantibodies, and inflammatory cells, highlighting the biological effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Nicholas P. Tschernia, Hillary Heiling, Allison M. Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J. Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne W. Beaven, Jonathan S. Serody, William A. Wood, Barbara Savoldo, Natalie S. Grover
Summary: Chimeric antigen receptor (CAR)-T cells targeting CD30 have shown high response rates and durable remissions in relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low toxicity rates and no neurotoxicity in our phase 2 study. Patient-reported outcomes (PROs) collected in our clinical trial showed that physical function and symptom burden of patients treated with CD30-directed CAR-T cells recovered to at least their baseline health by 1 month post infusion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Leonie K. de Klerk, Anuj K. Patel, Sarah Derks, Eirini Pectasides, Jeremy Augustin, Mohamed Uduman, Nihal Raman, Fahire G. Akarca, Nadine J. McCleary, James M. Cleary, Douglas A. Rubinson, Jeffrey W. Clark, Bridget Fitzpatrick, Lauren K. Brais, Megan E. Cavanaugh, Amanda J. Rode, Melissa G. Jean, Patrick H. Lizotte, Matthew J. Nazzaro, Mariano Severgnini, Hui Zheng, Charles S. Fuchs, Peter C. Enzinger, Adam J. Bass
Summary: This study indicates that single-agent pembrolizumab has limited efficacy in patients with esophageal cancer, but circulating CXCL10 at baseline appears to be a robust predictor of response. Upregulation of other T cell exhaustion markers in PD-L1-positive patients suggests that immunotherapy combinations may hold promise in refractory esophageal cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Geir Bjorklund, Lili Zou, Jun Wang, Christos T. Chasapis, Massimiliano Peana
Summary: Thioredoxin reductases (TrxRs) are enzymes that reduce thioredoxin, playing a crucial role in the antioxidant system within cells. Inhibition of TrxR is a key clinical goal to address redox balance disturbances. Current research focuses on the importance of TrxRs in cellular functions and the mechanisms of inhibition by metal ions or chemicals.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Oncology
Yinghao Zhao, Shengnan Jia, Kun Zhang, Lian Zhang
Summary: Lung cancer is a common and deadly cancer type, especially non-small cell lung cancer. The effectiveness of therapy and prognosis largely depend on the stage of the disease at diagnosis. Cytokines, which are important for cell communication, have been found to play a role in the development and treatment of lung cancer. This review aims to evaluate the potential of serum cytokine levels and other factors as targets for immunotherapy and prognostic indicators for lung cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Xuewen Yin, Hui Wang, Rutao Li, Xuming Song, Te Zhang, Yingkuan Liang, Yu-Zhong Chen, Xinnian Yu, Qixing Mao, Wenjie Xia, Bing Chen, Lin Xu, Gaochao Dong, Feng Jiang
Summary: Smoking history is associated with increased levels of tertiary lymphoid structures and chemokine CCL21, which impacts the efficacy of immunotherapy in patients with lung cancer. Tobacco exposure promotes CCL21 expression and enhances the interaction between CD4+T cells and CD20+B cells through the CCL21/CCR7 axis, leading to the formation of tertiary lymphoid structures. Furthermore, serum levels of CCL21 can serve as a reliable biomarker for predicting the efficacy of immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Benjamin Wolfson, S. Elizabeth Franks, James W. Hodge
Summary: Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. By combining cancer vaccines with multiple immune agents, such as checkpoint blockade antibodies, novel multifunctional molecules, adoptive cell therapy, and immune system agonists, it is believed that future cancer immunotherapy holds promise for effectively treating established tumors.
Article
Oncology
Meng He, Zi-Fan Chen, Li Zhang, Xiangyu Gao, Xiaoyi Chong, Hao-shen Li, Lin Shen, Jiafu Ji, Xiaotian Zhang, Bin Dong, Zi-Yu Li, Tang Lei
Summary: This study aimed to assess the correlation between CT-derived body composition parameters and SII and OS in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade. The study found that high SII and high SFA were associated with OS, while sarcopenia was not an independent prognostic factor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Priyanka H. Mazire, Bhaskar Saha, Amit Roy
Summary: Leishmania donovani causes visceral leishmaniasis in humans, while Leishmania infantum is the main agent for zoonotic VL. Challenges in chemotherapy include limited drugs, drug resistance, toxicity, and the need for parenteral administration, particularly in resource-limited countries. Immunocompromised individuals, especially HIV-1 infected, are at higher risk of VL. Developing successful immunotherapy is crucial in balancing beneficial Leishmania-specific responses and immune hyperactivation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Xin Jin, Danni Xie, Rui Sun, Wenyi Lu, Xia Xiao, Yibing Yu, Juanxia Meng, Mingfeng Zhao
Summary: In this study, dual-targeted CAR-T (123NL CAR-T) cells were developed to eradicate AML cells and selectively target immunosuppressive cells. The incorporation of a highly compact marker/suicide gene, RQR8, allowed for the elimination of CAR-T cells and cessation of their cytotoxicity. This approach can overcome the limitations of single-target CAR-T therapy in AML.
Review
Oncology
Chu Xiao, Tao Fan, Yujia Zheng, He Tian, Ziqin Deng, Jingjing Liu, Chunxiang Li, Jie He
Summary: With the advancements in cancer immunity research, it has been discovered that histone modifications play a crucial role in establishing antitumor immunological ability. Combining epigenetic drugs with immune checkpoint blockades or chimeric antigen receptor-T cell therapies shows promise in improving immunotherapy outcomes. The specific histone modification, H3K4me3, is deeply involved in regulating tumor immunogenicity, reshaping tumor immune microenvironment, and regulating immune cell functions. However, there is still uncertainty in integrating these theoretical foundations and optimizing available therapies. This review explores the mechanisms by which H3K4me3 and its modifiers regulate antitumor immunity and discusses the potential of combining H3K4me3-related agents with immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Alessandra Dondero, Martina Morini, Davide Cangelosi, Katia Mazzocco, Martina Serra, Grazia Maria Spaggiari, Gianluca Rotta, Annalisa Tondo, Franco Locatelli, Aurora Castellano, Francesca Scuderi, Angela Rita Sementa, Alessandra Eva, Massimo Conte, Alberto Garaventa, Cristina Bottino, Roberta Castriconi
Summary: This study used multiparametric flow cytometry to analyze the sensitivity of GD2 and B7-H3 surface expression in neuroblastoma patients, finding that MFC is highly sensitive and can rapidly and accurately assess bone marrow tumor burden, while also detecting GD2 low/negative neuroblastoma variants in relapsed patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao, Fan Wang
Summary: This study reveals the immunogenic heterogeneity of pMMR/MSS CRC and identifies GBP2 as a promising target for combinatorial therapy with immune checkpoint blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Beatrice Belmonte, Valeria Cancila, Alessandro Gulino, Mohsen Navari, Walter Arancio, Paolo Macor, Andrea Balduit, Sara Capolla, Gaia Morello, Davide Vacca, Ines Ferrara, Giorgio Bertolazzi, Carmela Rita Balistreri, Paolo Amico, Federica Ferrante, Antonino Maiorana, Tiziana Salviato, Pier Paolo Piccaluga, Alessandro Mangogna
Summary: PSGL-1, as the major ligand of selectins, plays a crucial role in immune cell tethering, rolling, and extravasation. Recent studies have identified a novel mechanism of PSGL-1-mediated immune suppression in the tumor microenvironment, positioning it as a critical checkpoint molecule in tumor immunotherapy. The high expression of PSGL-1 in lymphoproliferative disorders, particularly in T-cell lymphomas, suggests its potential as a target for immunotherapy. Through gene expression profiling and immunohistochemical analysis, PSGL-1 was found to be enriched in ALCLs, altering cell motility and viability, and presenting itself as a promising candidate for novel immunotherapeutic approaches.
Article
Oncology
Anna Maria Berghella, Anna Aureli, Angelica Canossi, Tiziana Del Beato, Alessia Colanardi, Patrizia Pellegrini
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2019)
Article
Neurosciences
Laura Brandolini, Marta Grannonico, Gianluca Bianchini, Alessia Colanardi, Pierluigi Sebastiani, Antonella Paladini, Alba Piroli, Marcello Allegretti, Giustino Varrassi, Silvia Di Loreto
NEUROTOXICITY RESEARCH
(2019)
Correction
Neurosciences
Laura Brandolini, Marta Grannonico, Gianluca Bianchini, Alessia Colanardi, Pierluigi Sebastiani, Antonella Paladini, Alba Piroli, Marcello Allegretti, Giustino Varrassi, Silvia Di Loreto
NEUROTOXICITY RESEARCH
(2019)
Article
Immunology
Anna Aureli, Sara Aboulaghras, Khadija Oumhani, Tiziana Del Beato, Pierluigi Sebastiani, Alessia Colanardi, Rajae El Aouad, Imane Ben El Barhdadi, Daniela Piancatelli
Article
Immunology
Daniela Piancatelli, Daniela Maccarone, Alessia Colanardi, Pierluigi Sebastiani, Fabrizio D'Anselmi, Samuele Iesari, Barbara Binda, Francesco Pisani
TRANSPLANTATION PROCEEDINGS
(2020)
Article
Urology & Nephrology
Daniela Piancatelli, Daniela Maccarone, Alessia Colanardi, Pierluigi Sebastiani, Katia Clemente, Samuele Iesari, Quirino Lai, Francesco Pisani
Article
Neurosciences
Marta Grannonico, Laura Brandolini, Giustino Varrassi, Pierluigi Sebastiani, Alessia Colanardi, Antonella Paladini, Alba Piroli, Marcello Allegretti, Silvia Di Loreto
Article
Immunology
Angelica Canossi, Khadija Oumhani, Tiziana Del Beato, Pierluigi Sebastiani, Alessia Colanardi, Anna Aureli
Summary: Spondyloarthropathies (SpA) are chronic inflammatory disorders that primarily affect the axial spine and asymmetrical peripheral joints. Genetic factors, including HLA-B27, play an important role in the pathogenesis of SpA. This study found that CD1E*01/01 genotype was associated with increased risk of SpA, while CD1E*01/02 genotype was associated with decreased risk. These findings suggest a potential genetic overlap between SpA and celiac disease, and provide insights for future therapeutic strategies.
Article
Biochemistry & Molecular Biology
Daniela Piancatelli, Anna Aureli, Pierluigi Sebastiani, Alessia Colanardi, Tiziana Del Beato, Lorenza Del Cane, Patrizia Sucapane, Carmine Marini, Silvia Di Loreto
Summary: This study found that serum levels of BDNF are reduced in patients with Alzheimer's disease, especially in females. Polymorphisms of the IL-1 alpha and BDNF genes appear to play a role in changes in serum BDNF, particularly in female patients, while no effects of other gene variants affecting oxidative stress have been found.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Cell Biology
Daniela Piancatelli, Sara Aboulaghras, Imane Ben El Barhdadi, Pierluigi Sebastiani, Tiziana Del Beato, Alessia Colanardi, Khadija Oumhani
Meeting Abstract
Cell Biology
Daniela Piancatelli, Daniela Maccarone, Fabrizio D'Anselmi, Pierluigi Sebastiani, Alessia Colanardi, Tiziana Del Beato, Ylenia Della Rocca, Barbara Binda, Alessandra Panarese, Davide Chiappori, Francesco Pisani
Meeting Abstract
Cell Biology
Anna Aureli, Khadija Oumhani, Imane Ben El Barhdadi, Tiziana Del Beato, Alessia Colanardi, Pierluigi Sebas-Tiani, Rajae El Aouad, Sara Aboulghras, Daniela Piancatelli
Meeting Abstract
Cell Biology
Angelica Canossi, Anna Aureli, Tiziana Del Beato, Giorgio Novelli, Oreste Buonomo, Giuseppe Sconocchia